Pharming Group NV

4 August 2011
Interim Financial Results

Sijmen de Vries, CEO
Karl Keegan, CFO

HEALTH ■ SCIENCE ■ PRODUCTS

Safe harbour statement

The information contained in this document and made verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purpose.

The Presentation does not form any part of an offer of, or invitation to apply for, securities in Pharming Group N.V. (the "Company").

The Presentation speaks as of its date. The Company assumes no obligation to notify or inform the recipient of any developments or changes occurring such date of this document that might render the contents of the Presentation untrue or inaccurate in whole or in part. In addition, no representation or warranty, express or implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any such information or opinions by the Company or any of its directors, members, officers, employees, agents or advisers.

The Presentation contains forward-looking statements, including statements about our beliefs and expectations. These statements are based on our current plans, estimates and projections, as well as our expectations of external conditions and events. Forward-looking statements involve inherent risks and uncertainties and speak only as of the date they are made. The Company undertakes no duty to and will not necessarily update any of them in light of new information or future events, except to the extent required by applicable law.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act.

Operational Highlights

- Rollout of Ruconest® in Europe progressing well
  - Q2, 2011 sales up 26% to €0.2 million
  - Reimbursement at national & local levels ongoing
- New data announced supporting efficacy of Rhucin® across all HAE attack locations
  - (7th C1INH deficiency workshop, Budapest, Hungary)
- Commercialization agreement signed with Megapharm for Ruconest® in Israel
- Protocol for Phase III study 1310 of Rhucin® amended
  - Primary endpoint modified
  - Increased patient numbers
  - Completion expected by Q3, 2012
- SPA agreement reached with the FDA on Phase III study 1310, announced earlier today
- Granting of US patent further extends protection of core technology platform

H1 2011 Overview

- €10.0 million received from Socius
  - €9.0 million received
  - plus €1.0 million from exercise of warrants
- DNage entered liquidation & subsequently deconsolidated
  - Curtails cash burn
  - €1.6 million operating cash outflow in HY1 2010 (nil in 2011)
- Entered financial lease for portion of new assets in use by Sanofi
  - Type of non dilutive funding

Financial Highlights

- Revenues & other income increased to €1.4 million (H1 2010: €0.1m)
- Operating costs decreased to €9.0 million (H1 2010: €10.1m)
  - Cash outflows of €8.9m (H1 2010: €8.4m ex. DNage)
  - but 2010 period included significant partnering cash income
- Significant reduction in net loss to €8.0 million (H1 2010: €28.0m)
  - Includes one-time €0.6m profit on discontinued operations (H1 2010: €1.7m loss)
- Cash at June 30, 2011 of €11.0 million (FY 2010: €10.5m)
  - Strengthened post period by private placement (€3.2m)

Deliverables

- EU & US commercialisation deals signed ✓
- EU launch of Ruconest® ✓
- Progress on US development pathway for Rhucin ® ✓
- Continue EU rollout of Ruconest ® **ongoing**
- Expand geographic coverage of Rhucin® franchise ✓ **ongoing**
- Expand rhC1-INH platform ✓ **ongoing**
  - Initiate reperfusion injury programmes
- Leverage potential of the platform **ongoing**
  - New proteins, new indications

Upcoming Milestones

- Continue EU rollout of Ruconest ®
- Expand geographic coverage of Rhucin® franchise
  - ROW Business Development initiatives on going
- Expand rhC1-INH platform
  - AMR ongoing
  - Ischaemia Reperfusion Injury evaluation ongoing
- Leverage potential of the platform
  - Follow up ongoing

Summary

Significant progress made during the period

Commercialisation

- Rollout of Ruconest® in Europe is progressing well
- Reimbursement at national & local levels is ongoing
- Commercialization agreement with Megapharm for Ruconest® in Israel
  - represents first step in global expansion of C1 Inhibitor franchise

Regulatory

- Clarity from the FDA on US regulatory pathway for Rhucin®
- Agreement with FDA on SPA reached

Financials

- Significant revenue growth and net loss reduction
- Increased cash position
- €10.0 million received from Socius

www.pharming.com

NYSE Euronext: PHARM